ReviewLiver international : official journal of the International Association for the Study of the Liver2016
Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications.
Review in Liver international : official journal of the International Association for the Study of the Liver, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 134 citations in OpenAlex.
- Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD.Clinical and translational science · 2021Trial
- Safety of Statins in an Asian Cohort with Biopsy Proven Metabolic Dysfunction-Associated Steatotic Liver Disease.Digestive diseases and sciences · 2026Article
- Systematic comparison of temporal hepatotoxicant-induced gene network responses across 3 liver test systems.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- The gut-liver axis in drug-induced liver injury (DILI): Interplay between gut microbiota, intestinal barrier, and immune system.Acta pharmaceutica Sinica. B · 2026Review
- Human Leukocyte Antigen (International journal of molecular sciences · 2026Review
- Anti-Tubercular Drug-Induced Liver Injury: Current Understanding and Emerging Directions.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Characteristic Changes in the Immune Landscape of Aging Liver: From Basic Mechanism to Clinical Transformation.Journal of immunology research · 2026Review
- Drug-induced liver injury from high-dose intravenous methylprednisolone: A rare but known adverse effect.World journal of gastrointestinal pathophysiology · 2025Article
- Khat-associated Autoimmune Hepatitis: A Review with RUCAM Analysis.Journal of clinical and translational hepatology · 2025Review
- Management of hepatotoxicity associated with CDK4/6 inhibitors and rechallenge strategies in metastatic hormone-positive, HER2-NEGATIVE BREAST CANCER.Journal of cancer research and clinical oncology · 2025Article
- High Grade Hepatotoxicity From Dual Checkpoint Inhibitors Is More Common in Hepatocellular Carcinoma Than Other Cancers.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Apple Cider Vinegar-Induced Hepatotoxicity: A Rare Case Report.Oxford medical case reports · 2025Article
- Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review.Journal of gastroenterology and hepatology · 2024Review
- Article
- miR-106b-5p protects against drug-induced liver injury by targeting vimentin to stimulate liver regeneration.MedComm · 2024Article
- Acetaminophen-induced liver injury at therapeutic doses in a young adult: a case report.Clinical journal of gastroenterology · 2024Article
- Phytochemistry, pharmacology, toxicology and detoxification ofFrontiers in pharmacology · 2024Review
- Drug-induced liver injury: a comprehensive review.Therapeutic advances in gastroenterology · 2023Review
- Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers.Antimicrobial agents and chemotherapy · 2022Article
- Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.Antimicrobial agents and chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In the past decade our understanding of idiosyncratic drug induced liver injury (IDILI) and the contribution of genetic susceptibility and the adaptive immune system to the pathogenesis of this disease process has grown tremendously. One of the characteristics of IDILI is that it occurs rarely and only in a subset of individuals with a presumed susceptibility to the drug. Despite a clear association between single nucleotide polymorphisms in human leukocyte antigen (HLA) genes and certain drugs that cause IDILI, not all individuals with susceptible HLA genotypes develop clinically significant liver injury when exposed to drugs. The adaptation hypothesis has been put forth as an explanation for why only a small percentage of susceptible individuals develop overt IDILI and severe injury, while the majority with susceptible genotypes develop only mild abnormalities that resolve spontaneously upon continuation of the drug. This spontaneous resolution is referred to as clinical adaptation. Failure to adapt or defective adaptation leads to clinically significant liver injury. In this review we explore the immuno-tolerant microenvironment of the liver and the mechanisms of clinical adaptation in IDILI with a focus on the role of immune-tolerance and cellular adaptive responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.